Edition:
United States

Array Biopharma Inc (ARRY.OQ)

ARRY.OQ on NASDAQ Stock Exchange Global Market

10.92USD
15 Dec 2017
Change (% chg)

$-0.20 (-1.80%)
Prev Close
$11.12
Open
$11.15
Day's High
$11.19
Day's Low
$10.75
Volume
4,403,743
Avg. Vol
980,497
52-wk High
$13.38
52-wk Low
$6.74

Chart for

About

Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer. The Company's programs include approximately three cancer drugs, binimetinib, encorafenib and selumetinib (partnered with AstraZeneca, PLC). Its... (more)

Overall

Beta: 1.92
Market Cap(Mil.): $2,151.54
Shares Outstanding(Mil.): 197.03
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 198.20 16.04
EPS (TTM): -- -- --
ROI: -- -11.76 34.69
ROE: -- -36.72 15.46

BRIEF-Array - In Exchange For $126.06 Million 3.00% Convertible Senior Notes Co Issued 2024 $126.06 Million Notes

* ARRAY BIOPHARMA - ‍ON DEC 1, IN EXCHANGE FOR $126.06 MILLION OF 3.00% CONVERTIBLE SENIOR NOTES DUE 2020 CO ISSUED 2024 NOTES OF $126.06 MILLION

Dec 04 2017

BRIEF-Array Biopharma reports initial results from novel immunotherapy combination at SITC annual meeting

* Array biopharma reports initial results from novel immunotherapy combination at the Society For Immunotherapy Of Cancer (SITC) 32nd annual meeting

Nov 13 2017

BRIEF-ARRAY BIOPHARMA REPORTS Q1 LOSS PER SHARE $0.22

* ARRAY BIOPHARMA REPORTS FINANCIAL RESULTS FOR THE FIRST QUARTER OF FISCAL 2018

Oct 31 2017

BRIEF-Array Biopharma announces proposed public offering of common stock

* Array Biopharma announces proposed public offering of common stock

Sep 13 2017

BRIEF-Array Biopharma announces FDA acceptance for review of Binimetinib and Encorafenib new drug applications for patients with advanced BRAF-mutant melanoma

* Array Biopharma announces FDA acceptance for review of Binimetinib and Encorafenib new drug applications for patients with advanced BRAF-mutant melanoma

Sep 12 2017

BRIEF-Array Biopharma appoints Curtis Oltmans as general counsel

* Array Biopharma appoints Curtis Oltmans as general counsel Source text for Eikon: Further company coverage:

Aug 14 2017

BRIEF-Array Biopharma reports Q4 loss per share $0.17

* Array Biopharma reports financial results for the fourth quarter and full year of fiscal 2017

Aug 09 2017

BRIEF-Amgen and Array BioPharma announce preclinical license and collaboration agreement

* Amgen and Array BioPharma announce preclinical license and collaboration agreement in inflammation

Jul 18 2017

BRIEF-Array Biopharma submits new drug applications to FDA

* Array Biopharma submits new drug applications to FDA for binimetinib and encorafenib in advanced melanoma

Jul 05 2017

Competitors

Earnings vs. Estimates